AZD8055

Catalog No.S1555

Molecular Weight(MW): 465.54

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Cited by 47 Publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Cell, 2015, 27(1):97-108

PubMed: 25544637 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Autophagy, 2019, 15(3):543-557

PubMed: 30269645 ( click the link to review the publication )

Sci Rep, 2019, 9(1):9805

PubMed: 31285446 ( click the link to review the publication )

Front Physiol, 2019, 10:167

PubMed: 30873046 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:5196028

PubMed: 31223619 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Cancer Res, 2018, 78(12):3176-3189

PubMed: 29661831 ( click the link to review the publication )

Cell Commun Signal, 2017, 10.1186/s12964-017-0164-3

PubMed: 28143584 ( click the link to review the publication )

Genome Biol, 2016, 17(1):149

PubMed: 27380875 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0154564

PubMed: 27128484 ( click the link to review the publication )

Cancer Res, 2015, 75(20):4398-406

PubMed: 26359452 ( click the link to review the publication )

Cell Rep, 2015, 11(3):446-59

PubMed: 25865887 ( click the link to review the publication )

Clin Sci, 2015, 128(8):517-26

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.C114.627778

PubMed: 25833948 ( click the link to review the publication )

Biochem J, 2015, 465(2):227-38

PubMed: 25353634 ( click the link to review the publication )

J Chromatogr A, 2015, 1388:267-73

PubMed: ( click the link to review the publication )

Proteomics, 2015, 10.1002/pmic.201400586

PubMed: 25764225 ( click the link to review the publication )

J Clin Invest, 2014, 10.1172/JCI73935

PubMed: 25415435 ( click the link to review the publication )
Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Res, 2014, 74(14):3947-58

PubMed: 24986516 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28880

PubMed: 24706460 ( click the link to review the publication )

Antioxid Redox Sign, 2014, 20(9):1382-95

PubMed: 24063548 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-837

PubMed: ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Mol Reprod Dev, 2014, 81(7):655-65

PubMed: 24753052 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6015-27

PubMed: 24970798 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Am J Transplant, 2013, 13(8):2035-43

PubMed: 23841834 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

Mol Oncol, 2013, 33:404-18

PubMed: 24444656 ( click the link to review the publication )

J Biol Chem, 2013, 288(49):35287-96

PubMed: 24133218 ( click the link to review the publication )

Mol Biol Cell, 2013, 24(23):3736-45

PubMed: 24088573 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 440(4):701-6

PubMed: 24103749 ( click the link to review the publication )

Oncol Lett, 2013, 5(2):717-721

PubMed: 23420667 ( click the link to review the publication )

Autophagy, 2012, 9(1):74-92

PubMed: 23196898 ( click the link to review the publication )

Exp Neurol, 2012, 233(2):799-806

PubMed: 22177999 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(9):1183-94

PubMed: 22305748 ( click the link to review the publication )

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features

First drug to inhibit both types of mTOR protein.

Targets

mTOR (truncated) ^[1] (MDA-MB-468 cells)	mTOR (full length) ^[1] (MDA-MB-468 cells)
0.13 nM	0.8 nM

In vitro

AZD8055 shows low activity (∼1,000-fold) against all PI3K isoforms (α, β, γ, δ) and other members of the PI3K-like kinase family (ATM and DNA-PK). AZD8055 inhibits the phosphorylation of mTORC1 (p70S6K and 4E-BP1) as well as phosphorylation of the mTORC2 (Akt) and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 can be fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. AZD8055 potently inhibits proliferation in U87MG, A549 and H838 cells with IC50 of 53, 50 and 20 nM, respectively. AZD8055 also induces autophagy and increased LC3-II levels in H838 and A549 cells. ^[1] AZD8055 decreases AML blast cell proliferation and cell cycle progression, reduces the clonogenic growth of leukemic progenitors and induces caspase-dependent apoptosis in leukemic cells but not in normal immature CD34+ cells. ^[2] AZD8055 indicates inhibitory against the pediatric preclinical testing program (PPTP) cell lines with IC50 of 24.7 nM and induces significant differences in EFS distribution. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
LU-139	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;lOIxzUUN3ME2wMlAzOzNzIN88US=>	M3r1SHNCVkeHUh?=
NCI-H720	MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIC5bW9KSzVyPUCuNFI6OzhizszN	MnW2V2FPT0WU
KARPAS-45	Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TBVmlEPTB;MD6wN\|M4OSEQvF2=	NYfh[npGW0GQR1XS
EW-3	M2rqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTBwMESwOVYh\|ryP	M16xd3NCVkeHUh?=
SBC-1	NH23[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYntNWZ1UUN3ME2wMlA1PThzIN88US=>	NUezWJBNW0GQR1XS
NCI-H209	M1Wzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjBTWM2OD1yLkC1OFU{KM7:TR?=	NYCwWWJWW0GQR1XS
EoL-1-cell	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXUTWM2OD1yLkC2OVY6KM7:TR?=	NFLPSlRUSU6JRWK=
H9	MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTBwME[2PVIh\|ryP	NFG2OFNUSU6JRWK=
AN3-CA	NFzOSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTBwMEe5OVEh\|ryP	MXzTRW5ITVJ?
HH	M1HCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojaTWM2OD1yLkC4NFA6KM7:TR?=	NWLCcnB{W0GQR1XS
KU812	MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TjcWlEPTB;MD6wPFA1OyEQvF2=	MnWzV2FPT0WU
DU-4475	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnoUVdxUUN3ME2wMlA5ODR5IN88US=>	M1rCfHNCVkeHUh?=
CTV-1	NH7ZPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTBwMEi2OFEh\|ryP	M33oWHNCVkeHUh?=
BV-173	NFvQUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;ONWlEPTB;MD6wPVA3OSEQvF2=	NGLJOplUSU6JRWK=
ES5	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\ZcpdKSzVyPUCuNFk{PSEQvF2=	MVjTRW5ITVJ?
G-402	NGqzNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHq5SY1KSzVyPUCuNFk6QCEQvF2=	NX74V29GW0GQR1XS
MV-4-11	NFLXOFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPrZpRYUUN3ME2wMlExOzR5IN88US=>	MlzOV2FPT0WU
NB69	NF3jbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2f1UGlEPTB;MD6xN\|Uh\|ryP	MUDTRW5ITVJ?
EGI-1	M4W4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTBwMUO1N\|Eh\|ryP	M3rM[3NCVkeHUh?=
EW-18	MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfVcJJKSzVyPUCuNVQxPzNizszN	Mlr2V2FPT0WU
ME-180	NV\pN\|ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVX2WYViUUN3ME2wMlE1PjhzIN88US=>	NF2xc3VUSU6JRWK=
D-283MED	NVLMZW9qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7KWGxKSzVyPUCuNVQ4OjNizszN	M3vFXnNCVkeHUh?=
NB14	M4LzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjGbHo1UUN3ME2wMlE3PDR5IN88US=>	MkHqV2FPT0WU
Ramos-2G6-4C10	NXXCXpl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\pU5VKSzVyPUCuNVY6QDNizszN	NGj4fXVUSU6JRWK=
NBsusSR	NHG5UXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTBwMUewNVkh\|ryP	Mn3MV2FPT0WU
LAMA-84	NVrn[FBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfkTWM2OD1yLkG4NFMzKM7:TR?=	MXfTRW5ITVJ?
NCI-H1581	NI[wSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIj5SGhKSzVyPUCuNVg6PjZizszN	MWTTRW5ITVJ?
A204	NWj6O\|lyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTBwMUi5O{DPxE1?	M{[zdXNCVkeHUh?=
A549	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTBwMUm1OUDPxE1?	NHyxcmtUSU6JRWK=
CAL-51	M1:1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rLbGlEPTB;MD6xPVY2OSEQvF2=	NX3hRmZGW0GQR1XS
NKM-1	MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fCNmlEPTB;MD6yNFAzQSEQvF2=	NH3CN\|BUSU6JRWK=
LoVo	M4fsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTBwMkCyNFIh\|ryP	MXfTRW5ITVJ?
HAL-01	M1LyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUKzNHNmUUN3ME2wMlIxOjl5IN88US=>	NXjjR\|FvW0GQR1XS
HCC2218	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTBwMkC2PFgh\|ryP	NFjR[IlUSU6JRWK=
BEN	M2D4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLITWM2OD1yLkKxNlk{KM7:TR?=	NHrhbXVUSU6JRWK=
LC-2-ad	NUTqTHJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTBwMkKwPFQh\|ryP	MUPTRW5ITVJ?
LXF-289	NYq4WJpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{D6dWlEPTB;MD6yOVA1OSEQvF2=	MmHqV2FPT0WU
HGC-27	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zuc2lEPTB;MD6yOlQyPCEQvF2=	MmPmV2FPT0WU
LK-2	M2C2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTBwMk[4NlQh\|ryP	MonlV2FPT0WU
CTB-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLo[nRKSzVyPUCuNlczOTVizszN	NEDENIdUSU6JRWK=
697	M{fGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTBwMkezOlch\|ryP	NF\UcphUSU6JRWK=
ES7	NWf1RnRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTBwMkezPFMh\|ryP	NWO0bWhWW0GQR1XS
MG-63	NVPscJllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkX0TWM2OD1yLkK3OFA4KM7:TR?=	MoLjV2FPT0WU
T47D	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrtRWdKSzVyPUCuNlc1PzVizszN	MoHyV2FPT0WU
RPMI-8226	M3jtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PxfGlEPTB;MD6yPFU5QSEQvF2=	NHnuTZpUSU6JRWK=
NCI-H292	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDv[pI1UUN3ME2wMlI6OTZ2IN88US=>	NW\pNHU6W0GQR1XS
HT	NV64Xnh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnr[m1KSzVyPUCuNlk{QCEQvF2=	NWDWU457W0GQR1XS
A3-KAW	Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;4TWM2OD1yLkK5O\|Qh\|ryP	M{jpXnNCVkeHUh?=
LB2241-RCC	M{X2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnG4TWM2OD1yLkOwNVk5KM7:TR?=	NEDDZnVUSU6JRWK=
BB65-RCC	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\O[5ZxUUN3ME2wMlMxQDB3IN88US=>	M3zmWnNCVkeHUh?=
G-401	NFiwbHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnuVIxGUUN3ME2wMlMxQTh4IN88US=>	M{DDPHNCVkeHUh?=
TYK-nu	M{T3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfxSYpVUUN3ME2wMlMyQDZ2IN88US=>	MX;TRW5ITVJ?
NCI-SNU-1	M1\aeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTBwM{KzN\|Eh\|ryP	MYTTRW5ITVJ?
CHL-1	NYniVVR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33zVGlEPTB;MD6zNlcxOyEQvF2=	Mn3uV2FPT0WU
P30-OHK	MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUW2TI9qUUN3ME2wMlMzPzB3IN88US=>	NUfm[I1GW0GQR1XS
PA-1	MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTBwM{O2NVkh\|ryP	MUfTRW5ITVJ?
LB1047-RCC	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{Xre2lEPTB;MD6zOFA1PyEQvF2=	M3nRXXNCVkeHUh?=
EM-2	NXPOUpRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rhbmlEPTB;MD6zOFE5QCEQvF2=	MkTNV2FPT0WU
VA-ES-BJ	NWrxO\|drT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHJTWM2OD1yLkO0NlY5KM7:TR?=	M3HYdXNCVkeHUh?=
NCI-H520	NI\zTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3DZohKUUN3ME2wMlM1QDN2IN88US=>	NFXkRlhUSU6JRWK=
ECC10	M4XHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTBwM{WwN\|Uh\|ryP	NFTHT\|FUSU6JRWK=
LNCaP-Clone-FGC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7v[HFKSzVyPUCuN\|U{OTRizszN	NWrIR4R3W0GQR1XS
ES8	M3H4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zWVmlEPTB;MD6zOlU2OyEQvF2=	NVuw[mZKW0GQR1XS
HuO-3N1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2ezS2lEPTB;MD6zPFM4QSEQvF2=	MnnzV2FPT0WU
L-363	NHfqXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4K5bGlEPTB;MD6zPVAzPiEQvF2=	M4SyTHNCVkeHUh?=
SK-LU-1	NXvuNJROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTqTWM2OD1yLkO5NlA5KM7:TR?=	MnixV2FPT0WU
MCF7	NIO2bFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jDb2lEPTB;MD60NFU{KM7:TR?=	MWTTRW5ITVJ?
HuO9	NHqwRolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTzT5NuUUN3ME2wMlQxPjZ5IN88US=>	MnvDV2FPT0WU
BHT-101	Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfUTWM2OD1yLkSwO\|g4KM7:TR?=	NEfRdVBUSU6JRWK=
MZ2-MEL	MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDtSpNuUUN3ME2wMlQxQDh{IN88US=>	Mkn4V2FPT0WU
NOS-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTBwNEGwO\|Qh\|ryP	NWrxcmhpW0GQR1XS
NEC8	Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\5TWM2OD1yLkSxOlk2KM7:TR?=	M3zVVXNCVkeHUh?=
COR-L88	NV\SUVFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXT3PYY5UUN3ME2wMlQzOjZ5IN88US=>	MnXSV2FPT0WU
MFM-223	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rLS2lEPTB;MD60NlYyPyEQvF2=	NELHfIhUSU6JRWK=
HSC-3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PyN2lEPTB;MD60NlkxQCEQvF2=	NUXH[5JvW0GQR1XS
OVCAR-5	MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PBUGlEPTB;MD60Nlk{OyEQvF2=	MmrRV2FPT0WU
MFE-280	NIKzdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHmd3oyUUN3ME2wMlQ{ODN{IN88US=>	NHTWZ2VUSU6JRWK=
KP-N-YS	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rMTGlEPTB;MD60N\|A4KM7:TR?=	NHfHZm5USU6JRWK=
EPLC-272H	NX72eWVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4frXWlEPTB;MD60N\|A4PyEQvF2=	NYXnUHZ6W0GQR1XS
KE-37	MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLzTWM2OD1yLkSzNlQ4KM7:TR?=	NIe4VphUSU6JRWK=
HuH-7	Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPyV2hnUUN3ME2wMlQ{Ozd{IN88US=>	NWf6R49wW0GQR1XS
CHP-212	NV3qe4QyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfheoNzUUN3ME2wMlQ{Pjl5IN88US=>	M{\iTHNCVkeHUh?=
SK-MES-1	M1XGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHXTWM2OD1yLkSzPFQ5KM7:TR?=	MVzTRW5ITVJ?
SJSA-1	NXHuR2VPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTBwNES1OVQh\|ryP	M4qwbHNCVkeHUh?=
QIMR-WIL	NVrsT4tnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\4WWNKSzVyPUCuOFUyPSEQvF2=	M3fZOXNCVkeHUh?=
ES4	NWjjRXBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTBwNEWzN\|Yh\|ryP	M33Id3NCVkeHUh?=
TI-73	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vPOmlEPTB;MD60OVY5PiEQvF2=	MVPTRW5ITVJ?
COLO-684	NGS1VFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37BeWlEPTB;MD60OVczPiEQvF2=	NWjC[oY{W0GQR1XS
GCIY	NEHkXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHlTWM2OD1yLkS1O\|U1KM7:TR?=	NYLzTWJXW0GQR1XS
JVM-3	NFrad21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWr5cJFvUUN3ME2wMlQ3Ojl{IN88US=>	NIL1VHRUSU6JRWK=
MPP-89	M3jOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX:zOnJnUUN3ME2wMlQ3QTR5IN88US=>	NWC0U5B{W0GQR1XS
M14	M3fTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXUbGdKSzVyPUCuOFcyPyEQvF2=	MWrTRW5ITVJ?
SW962	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonNTWM2OD1yLkS3NVkh\|ryP	M3zp[XNCVkeHUh?=
VM-CUB-1	NX:4XoJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jiPWlEPTB;MD60O\|I5PiEQvF2=	MVnTRW5ITVJ?
A101D	M1T3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYH1dldGUUN3ME2wMlQ5QTZ6IN88US=>	NX7FToR6W0GQR1XS
DB	NXXDXlJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTBwNUCwNlEh\|ryP	NF;DfINUSU6JRWK=
KNS-62	NXP2XWJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTBwNUC1Olgh\|ryP	NWrtTJN[W0GQR1XS
NCI-H460	NXzmTpV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTBwNUC1PVch\|ryP	MVXTRW5ITVJ?
MDA-MB-361	MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;zcHdFUUN3ME2wMlUxQDdizszN	NFvC[2FUSU6JRWK=
DOK	NFvufYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTBwNUGzN\|Mh\|ryP	MnjRV2FPT0WU
CAL-39	M2CxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7tUm9KSzVyPUCuOVIzPjhizszN	NIG4UYZUSU6JRWK=
HT-1080	NYO2[WxHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVX0Z\|lmUUN3ME2wMlUzPTR\|IN88US=>	NX\3OIFMW0GQR1XS
GR-ST	NHHNSnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1e5XGlEPTB;MD61N\|AyPSEQvF2=	MYfTRW5ITVJ?
J-RT3-T3-5	M{PKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zrVGlEPTB;MD61N\|E6PSEQvF2=	MUPTRW5ITVJ?
NCI-H1793	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTBwNUO0OFch\|ryP	NH3lc2hUSU6JRWK=
NCI-H1355	NIDDcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnG3TWM2OD1yLkWzPFc5KM7:TR?=	MnfKV2FPT0WU
YH-13	M2nFWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTBwNUS5N\|gh\|ryP	NX;DbFdjW0GQR1XS
LOXIMVI	MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTBwNUWxNlMh\|ryP	NY\kXGJmW0GQR1XS
ES1	NEPnWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mki1TWM2OD1yLkW1OVE5KM7:TR?=	MYLTRW5ITVJ?
GAMG	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFK0SmJKSzVyPUCuOVU3PThizszN	M4jYXXNCVkeHUh?=
SK-MEL-28	NIjJO3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTBwNUW5NUDPxE1?	NX74S4w3W0GQR1XS
KG-1	NX:zXFZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjt[291UUN3ME2wMlU3QDh2IN88US=>	MoPlV2FPT0WU
HOS	M3vtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnlNlF2UUN3ME2wMlU4OTl{IN88US=>	NUfXNHlFW0GQR1XS
PANC-08-13	NYPwSGh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnDfHV7UUN3ME2wMlU4Ozh7IN88US=>	MYDTRW5ITVJ?
SW780	MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjKdXNoUUN3ME2wMlU4PTl3IN88US=>	NGDzUIpUSU6JRWK=
MDA-MB-175-VII	NGTIWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoW5TWM2OD1yLkW3O\|QyKM7:TR?=	NV:1cpJUW0GQR1XS
MSTO-211H	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfCU45KSzVyPUCuOVc4PTFizszN	MXnTRW5ITVJ?
ML-2	MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPqNIpJUUN3ME2wMlU5PDd6IN88US=>	NIrrWlJUSU6JRWK=
SCC-4	M{jxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1P5UWlEPTB;MD61PFU1OSEQvF2=	NGHRPIdUSU6JRWK=
NCI-H1048	NGLIUmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLwTWM2OD1yLkW4OlQ2KM7:TR?=	Mkf0V2FPT0WU
NCI-H28	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvyTWM2OD1yLkW4Olc2KM7:TR?=	M4fOXnNCVkeHUh?=
BCPAP	NYnHSnFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrWUGxQUUN3ME2wMlU5PzlzIN88US=>	NUHmdolGW0GQR1XS
PC-14	NX;WWFVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;iTHNKSzVyPUCuOVg6PyEQvF2=	MUDTRW5ITVJ?
OAW-42	M13C[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fTXWlEPTB;MD61PVE3OiEQvF2=	MnLZV2FPT0WU
IA-LM	NYHLXW5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jHdWlEPTB;MD61PVYxQSEQvF2=	NGjRXW9USU6JRWK=
Hs-578-T	NGT5RYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmX4TWM2OD1yLkW5PFUyKM7:TR?=	M{jF[nNCVkeHUh?=
H4	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLHTWM2OD1yLk[wNFk1KM7:TR?=	MW\TRW5ITVJ?
HL-60	NIfwV\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU[0Nol6UUN3ME2wMlYxOzVzIN88US=>	NIj1SZhUSU6JRWK=
NCI-H1437	M4f3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzNTHJKSzVyPUCuOlA3OTlizszN	MWfTRW5ITVJ?
KGN	NXHZNFhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTBwNkGwOFkh\|ryP	NVq4N4RtW0GQR1XS
NCI-H2452	NVvjdGJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fGbGlEPTB;MD62NVkyPyEQvF2=	NYT5UpB1W0GQR1XS
BFTC-905	NVPBb4gxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTBwNkKxNlYh\|ryP	MkPYV2FPT0WU
CAMA-1	NFLYU3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTBwNkKxOVIh\|ryP	MV3TRW5ITVJ?
SK-NEP-1	NF3lXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjTSFBrUUN3ME2wMlYzPTB{IN88US=>	MmTHV2FPT0WU
NCI-H522	NXLze2N7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk[0TWM2OD1yLk[yPVkzKM7:TR?=	MUfTRW5ITVJ?
SW1710	Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPYTWM2OD1yLk[zNVY4KM7:TR?=	MofLV2FPT0WU
RVH-421	MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1W2UmlEPTB;MD62N\|Y{QSEQvF2=	MXrTRW5ITVJ?
SK-MEL-2	NYfhTZV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTBwNkSxOVMh\|ryP	NXy1TmljW0GQR1XS
KYSE-150	NFfKWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmq5TWM2OD1yLk[2NVg3KM7:TR?=	NGLHNlVUSU6JRWK=
MOLT-13	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvIN5Q4UUN3ME2wMlY3PTN5IN88US=>	NXzvN3dYW0GQR1XS
SK-OV-3	MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPtTWM2OD1yLk[3NVg4KM7:TR?=	NFy3ToFUSU6JRWK=
IGROV-1	MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rOXWlEPTB;MD62O\|Q2KM7:TR?=	NE[0bldUSU6JRWK=
MOLT-4	NF33fZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\YTWM2OD1yLk[3Olg6KM7:TR?=	MV;TRW5ITVJ?
MEL-HO	M2TWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTBwNke3OVIh\|ryP	NHrNflZUSU6JRWK=
MDA-MB-157	NFW1SWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofjTWM2OD1yLk[3PFEh\|ryP	NUHx[nBCW0GQR1XS
MN-60	MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fzTGlEPTB;MD62O\|g1PiEQvF2=	NH3nSJpUSU6JRWK=
EFO-27	NX;EPHdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVS5VINIUUN3ME2wMlY4QTd7IN88US=>	NX7yT4FPW0GQR1XS
HO-1-N-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTBwNkiwOlQh\|ryP	MXfTRW5ITVJ?
TE-5	M1PUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXBVXdKSzVyPUCuOlg1ODVizszN	MmXkV2FPT0WU
EW-22	M1;RTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXG5NGZ1UUN3ME2wMlY5PDR2IN88US=>	MYHTRW5ITVJ?
SW982	NYrSb3dIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rrNmlEPTB;MD62PFUxOSEQvF2=	NX3USFR1W0GQR1XS
SF295	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTBwNki1NFch\|ryP	M2W4TnNCVkeHUh?=
WM-115	NIK0XYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTBwNki5NlQh\|ryP	Mmr5V2FPT0WU
COLO-800	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TEc2lEPTB;MD62PVgyOyEQvF2=	Ml3zV2FPT0WU
NTERA-S-cl-D1	M1:yUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTBwN{CwOlMh\|ryP	MUPTRW5ITVJ?
NCI-H1648	NECxbXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnvbFNvUUN3ME2wMlcxOTd\|IN88US=>	NI\hUmVUSU6JRWK=
NB5	NUH6[3FFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmD3TWM2OD1yLkewN\|E6KM7:TR?=	MY\TRW5ITVJ?
ATN-1	NH\uWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TMZmlEPTB;MD63NFU6KM7:TR?=	MoPyV2FPT0WU
NUGC-3	NFG5TWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTBwN{C2PVEh\|ryP	M{ntNnNCVkeHUh?=
22RV1	NFS0b2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7UN4ZpUUN3ME2wMlcxPzF5IN88US=>	M3;0b3NCVkeHUh?=
8305C	NVLCOlZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTBwN{C3OVUh\|ryP	NF\NOWxUSU6JRWK=
EFM-19	MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfDUXJKSzVyPUCuO\|A5PDdizszN	M{nuUnNCVkeHUh?=
PC-3	NGGzTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnX5TWM2OD1yLkeyNlMh\|ryP	MU\TRW5ITVJ?
C32	M2HkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFWwTFFKSzVyPUCuO\|I1QDRizszN	MnL4V2FPT0WU
MC-IXC	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jmU2lEPTB;MD63NlcyQCEQvF2=	NHXwflZUSU6JRWK=
OMC-1	NYfmcnBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHtSXFKSzVyPUCuO\|I4OzhizszN	M3m5enNCVkeHUh?=
HTC-C3	NIGyelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4O3WWlEPTB;MD63N\|E4OiEQvF2=	M1\oXXNCVkeHUh?=
RPMI-7951	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzN[FJKSzVyPUCuO\|M2OzNizszN	M4LCNXNCVkeHUh?=
AsPC-1	NGLPRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\qNlRKSzVyPUCuO\|M4QTVizszN	NF61b3FUSU6JRWK=
CAKI-1	M{XrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFf6[ZZKSzVyPUCuO\|Q3OjlizszN	NIrhdWRUSU6JRWK=
MHH-PREB-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXyTWM2OD1yLke0O\|M3KM7:TR?=	NUXWWIcxW0GQR1XS
HLE	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDSTWM2OD1yLke0PFQ1KM7:TR?=	NYjLXHBNW0GQR1XS
A375	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfLTWM2OD1yLke1NVk{KM7:TR?=	M3HvS3NCVkeHUh?=
RS4-11	M13idGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{j3R2lEPTB;MD63OVk1OyEQvF2=	MX\TRW5ITVJ?
U-2-OS	M3\5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfrS\|hKSzVyPUCuO\|U6PyEQvF2=	MmjPV2FPT0WU
NCI-H747	M333[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTSc5FKSzVyPUCuO\|U6QTFizszN	M1fCZXNCVkeHUh?=
NCI-H1623	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7xTWM2OD1yLke2NlYyKM7:TR?=	NGTGOlFUSU6JRWK=
DMS-273	NVPDUWxLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTBwN{[5NlIh\|ryP	M3vKT3NCVkeHUh?=
PSN1	MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFu3OpBKSzVyPUCuO\|cxPTdizszN	MWDTRW5ITVJ?
LU-99A	NHfZ[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXiTWM2OD1yLke3OlQ6KM7:TR?=	NWO5eJJbW0GQR1XS
CAL-12T	NV;JfHU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLQfFE5UUN3ME2wMlc5ODJ7IN88US=>	NYHEW2Z[W0GQR1XS
KYSE-140	M3\Wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTBwN{ixOlgh\|ryP	MX\TRW5ITVJ?
VMRC-RCZ	Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDSeJdKSzVyPUCuO\|g1QDJizszN	NHLjdG1USU6JRWK=
Ca9-22	Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XlNGlEPTB;MD63PFc{PiEQvF2=	MVTTRW5ITVJ?
NCI-H1563	MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvDTWM2OD1yLke4PVI3KM7:TR?=	MlXZV2FPT0WU
NCI-H650	NVrjPGZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXyxRlk6UUN3ME2wMlc6OTR2IN88US=>	MnntV2FPT0WU
DOHH-2	NVzqTZhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrkOodKSzVyPUCuO\|k{OyEQvF2=	Mn\XV2FPT0WU
OE33	NVT4d2RoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTBwN{m5NVQh\|ryP	M3Hsb3NCVkeHUh?=
CAL-62	MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHntd5lKSzVyPUCuO\|k6OjRizszN	MYTTRW5ITVJ?
NCI-H1770	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjiXHpmUUN3ME2wMlgxOjFizszN	NFTuOYNUSU6JRWK=
SN12C	M2fkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4iw[2lEPTB;MD64NFY3QCEQvF2=	M{nTNnNCVkeHUh?=
HPAF-II	NIjFZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mle1TWM2OD1yLkiwO\|k1KM7:TR?=	MlX4V2FPT0WU
SNU-423	MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTBwOEG0NlIh\|ryP	NHO1N4RUSU6JRWK=
A704	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTBwOEG3PVgh\|ryP	NVm3O\|drW0GQR1XS
OVCAR-4	M3Pu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTBwOEG5NVEh\|ryP	MYHTRW5ITVJ?
NCI-H2347	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVO5bZFDUUN3ME2wMlgzPDBzIN88US=>	MWXTRW5ITVJ?
OCUB-M	M{XzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXna[Vd2UUN3ME2wMlgzPjd3IN88US=>	NYrVT\|dGW0GQR1XS
KYSE-450	M4XSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LDT2lEPTB;MD64NlczPSEQvF2=	NVL6TXBJW0GQR1XS
PFSK-1	M1fWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHnWI5KSzVyPUCuPFMxOzlizszN	M{H2O3NCVkeHUh?=
A431	NVHhTpF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETT[mVKSzVyPUCuPFMyOTZizszN	MXTTRW5ITVJ?
MHH-ES-1	M1r6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLYOFNKSzVyPUCuPFM1PTdizszN	MUjTRW5ITVJ?
HD-MY-Z	M2TZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\B[HhKSzVyPUCuPFQxQTJizszN	NVj6bpZPW0GQR1XS
RT-112	M2nDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XoeWlEPTB;MD64OFk{PyEQvF2=	MWPTRW5ITVJ?
KU-19-19	M{DE[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTBwOEWxNlEh\|ryP	MXzTRW5ITVJ?
HCC1569	NETvbIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTBwOEWyNFch\|ryP	NXS1VG03W0GQR1XS
RPMI-8866	M2D0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1q3bWlEPTB;MD64OVgzOiEQvF2=	MkToV2FPT0WU
CAL-120	MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3ftNGlEPTB;MD64OlA1OSEQvF2=	NFXUU4tUSU6JRWK=
CAL-33	MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDQTY9KSzVyPUCuPFY1QTVizszN	M{OwV3NCVkeHUh?=
RKO	NHvEfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkToTWM2OD1yLki2PFE4KM7:TR?=	M32zd3NCVkeHUh?=
HCC1419	NVKzN\|Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;jTWM2OD1yLki2PVI5KM7:TR?=	MVrTRW5ITVJ?
CP50-MEL-B	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWP6bIRzUUN3ME2wMlg5Ozh2IN88US=>	MmDOV2FPT0WU
BPH-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTBwOEizPVUh\|ryP	NUDzV3k3W0GQR1XS
SF126	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\URXhKSzVyPUCuPFg4OTRizszN	NULubld[W0GQR1XS
BHY	NF;6NVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTBwOEi3N\|Qh\|ryP	M1;aWHNCVkeHUh?=
BxPC-3	Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTFTWM2OD1yLki4PFM{KM7:TR?=	NWLjR29LW0GQR1XS
ETK-1	NYfvc3l2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXFXI5KSzVyPUCuPFk{PzJizszN	MoXOV2FPT0WU
NCI-H1573	NEDtbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLXTWM2OD1yLkmwNlI6KM7:TR?=	NGq0U\|VUSU6JRWK=
C-33-A	NIXRO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{W4N2lEPTB;MD65NFQ1OiEQvF2=	MVXTRW5ITVJ?
UACC-893	MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrsTWM2OD1yLkmyPFU2KM7:TR?=	M{LPOHNCVkeHUh?=
RXF393	NYjU[JN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTBwOUK4PVch\|ryP	MoXsV2FPT0WU
MIA-PaCa-2	NXy4WlJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13SbGlEPTB;MD65NlkzOiEQvF2=	NF3mPWdUSU6JRWK=
HCC1806	NIn4NWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTtTWM2OD1yLkmzNlU3KM7:TR?=	NYrZO2RrW0GQR1XS
DMS-114	NHjk[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTBwOUO2O\|ch\|ryP	M2K3N3NCVkeHUh?=
MOLT-16	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrvXW9KSzVyPUCuPVM5PDVizszN	M4TDWXNCVkeHUh?=
ACN	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXjNpRxUUN3ME2wMlk1Ojd5IN88US=>	NYHI[nU3W0GQR1XS
SNU-449	MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXO0cIt1UUN3ME2wMlk2QTJ2IN88US=>	M3TyTnNCVkeHUh?=
A427	NYTSc4cyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fNTWlEPTB;MD65OlE6QCEQvF2=	NInBVohUSU6JRWK=
DEL	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWOyemVRUUN3ME2wMlk3Pzd\|IN88US=>	MUXTRW5ITVJ?
NCI-H1792	M1O2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4C4dGlEPTB;MD65O\|ExOSEQvF2=	MnLWV2FPT0WU
A2058	M{PyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml6zTWM2OD1yLkm3N\|Yh\|ryP	NHzHNIZUSU6JRWK=
SW13	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTBwOUizPVIh\|ryP	M4jwVHNCVkeHUh?=
T98G	M4XnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfoTWM2OD1zLkCxN\|Y1KM7:TR?=	NInRNXRUSU6JRWK=
LU-134-A	NEHwVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\xdVlKSzVyPUGuNFI3PzVizszN	NFzyRnFUSU6JRWK=
GI-ME-N	NHnwVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPSbZZKSzVyPUGuNFI5OjdizszN	Ml:3V2FPT0WU
D-423MG	Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHNcm9IUUN3ME2xMlAzQTZ\|IN88US=>	MYDTRW5ITVJ?
PANC-03-27	NXnyZm5FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTFwMEOxOFEh\|ryP	MoD4V2FPT0WU
P12-ICHIKAWA	NITUXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUn0XJZmUUN3ME2xMlA{PDB4IN88US=>	NGTVRZNUSU6JRWK=
SCH	M4fQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HkcmlEPTB;MT6wN\|Q2KM7:TR?=	NIntNIRUSU6JRWK=
D-566MG	MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnSdlBKSzVyPUGuNFY4OjZizszN	MnLaV2FPT0WU
OS-RC-2	MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXI[41XUUN3ME2xMlA4QTRizszN	MXvTRW5ITVJ?
KOSC-2	NWPjd3NjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rVe2lEPTB;MT6wPFAzOSEQvF2=	NHrsc\|lUSU6JRWK=
SH-4	MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4f0XmlEPTB;MT6wPFQ{OSEQvF2=	M2j1O3NCVkeHUh?=
786-0	MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTFwMEi5N\|Qh\|ryP	NIjscYtUSU6JRWK=
Mewo	NIfaZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTFwMEmyOFgh\|ryP	MWjTRW5ITVJ?
AGS	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPXTWM2OD1zLkC5OFU6KM7:TR?=	M2foNHNCVkeHUh?=
Daoy	NUjQb3R4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vDPGlEPTB;MT6wPVYzQCEQvF2=	MUjTRW5ITVJ?
SW48	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlX3TWM2OD1zLkGwPVEyKM7:TR?=	M2PoUHNCVkeHUh?=
KYSE-180	NHnPSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjBW2ZzUUN3ME2xMlEyODJzIN88US=>	NWLvOJBGW0GQR1XS
NH-12	M37kOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fmcGlEPTB;MT6xNVI{PyEQvF2=	NWD0ZW1sW0GQR1XS
BE-13	M{PZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmf1TWM2OD1zLkGxO\|U6KM7:TR?=	MoO2V2FPT0WU
ES3	M{niVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rpVmlEPTB;MT6xN\|E4OSEQvF2=	NY\DNWZyW0GQR1XS
NCI-H1092	Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTFwMUO0JO69VQ>?	M33nUHNCVkeHUh?=
NCI-H1755	NYSwZoFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUT0Z25UUUN3ME2xMlE{QTRzIN88US=>	MnjYV2FPT0WU
EKVX	NEnDc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4KyV2lEPTB;MT6xOFAxOSEQvF2=	MkP3V2FPT0WU
NB13	MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHxTWM2OD1zLkG0OFUh\|ryP	NXLmOWR[W0GQR1XS
NCI-H2405	M1y3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPoT\|lKSzVyPUGuNVQ2PzRizszN	MoX3V2FPT0WU
LS-411N	M2L3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLwVIJLUUN3ME2xMlE2ODF5IN88US=>	MWjTRW5ITVJ?
MDA-MB-453	M3fFeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDlfGNKSzVyPUGuNVU3OjRizszN	MnPkV2FPT0WU
SCC-15	M13USWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTFwMU[5OVYh\|ryP	NFW5cZZUSU6JRWK=
C2BBe1	NHvzRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjSTWM2OD1zLkG3NFU3KM7:TR?=	NF;BWXlUSU6JRWK=
HT-144	M3K2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\lTWM2OD1zLkG3NFch\|ryP	MkS4V2FPT0WU
HEC-1	M1rrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7JTWM2OD1zLkG3OlI4KM7:TR?=	NEj4OFBUSU6JRWK=
HCE-T	NWTHbnZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnFXJh2UUN3ME2xMlE4QTh\|IN88US=>	NWntVlV4W0GQR1XS
IST-MEL1	MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInScXJKSzVyPUGuNVkxQDJizszN	NHvS[YZUSU6JRWK=
Detroit562	MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjMTmZKSzVyPUGuNVk1OzlizszN	NXrU[VE4W0GQR1XS
A4-Fuk	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV:xRYh{UUN3ME2xMlIxPDRzIN88US=>	NHToPXVUSU6JRWK=
HDLM-2	NXW1WFNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTFwMkGzNlYh\|ryP	M13uTHNCVkeHUh?=
MKN7	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vjdmlEPTB;MT6yNVcxOiEQvF2=	NHXEVmpUSU6JRWK=
MDA-MB-415	M2HUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTFwMkG3NFIh\|ryP	M4H4Z3NCVkeHUh?=
BT-20	MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvzXYlKSzVyPUGuNlI1PDRizszN	MmLjV2FPT0WU
NCI-H2030	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXHd3ZTUUN3ME2xMlI1OTB4IN88US=>	MWXTRW5ITVJ?
LS-123	NIXkeppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTFwMkS3OVMh\|ryP	NVPkdFRKW0GQR1XS
SK-MEL-3	MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnZcnFFUUN3ME2xMlI1Pzd4IN88US=>	M1;CNnNCVkeHUh?=
KS-1	M3HUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LnZWlEPTB;MT6yOVE4OSEQvF2=	MWLTRW5ITVJ?
LU-65	M3\r[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NET3OGRKSzVyPUGuNlU3ODZizszN	NWfaZWxYW0GQR1XS
NCI-H596	M1;UOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjySYNKSzVyPUGuNlU6OjlizszN	NWCwVoRoW0GQR1XS
KYSE-410	M1;iXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjkeYtMUUN3ME2xMlI4ODF2IN88US=>	MW\TRW5ITVJ?
NCI-H2228	NWm4XoVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfHV4Q5UUN3ME2xMlI4OTZ5IN88US=>	MmPJV2FPT0WU
LN-405	M1;qPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4i4VmlEPTB;MT6yPFAzOSEQvF2=	NHHmZlhUSU6JRWK=
8505C	NXTwcVF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXzTWM2OD1zLkK4PFI{KM7:TR?=	NXK2WGNPW0GQR1XS
BFTC-909	M{fYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHewUHVKSzVyPUGuNlk1OzRizszN	MljBV2FPT0WU
OC-314	NFjW[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NET1VpJKSzVyPUGuNlk6OjlizszN	MmS4V2FPT0WU
NMC-G1	M4P3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLETWM2OD1zLkOxNVM2KM7:TR?=	M2LXN3NCVkeHUh?=
SKG-IIIa	NYPEeINST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\JTWM2OD1zLkOxOFI5KM7:TR?=	NXK3bGkyW0GQR1XS
GAK	M{Szcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{P5NmlEPTB;MT6zNVg2QCEQvF2=	MmjsV2FPT0WU
D-263MG	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\GUoJlUUN3ME2xMlMzPjRzIN88US=>	MUPTRW5ITVJ?
NCI-H446	NXfWXGl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTFwM{K5NFIh\|ryP	MYHTRW5ITVJ?
TGBC1TKB	MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDabW5KSzVyPUGuN\|I6QThizszN	MYXTRW5ITVJ?
GCT	NXzKXohVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTFwM{SzOFUh\|ryP	NWT4SpNEW0GQR1XS
COR-L23	NHrUd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTFwM{S4OFUh\|ryP	Ml:xV2FPT0WU
TK10	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXpPXBKUUN3ME2xMlM2Pzl5IN88US=>	MVTTRW5ITVJ?
ES6	NXm4fHFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTFwM{[zO\|Yh\|ryP	MVzTRW5ITVJ?
SW1088	NIXXR\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3q0N2lEPTB;MT6zOlYyOiEQvF2=	MYjTRW5ITVJ?
AM-38	MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zvTGlEPTB;MT6zO\|E6QSEQvF2=	MmXnV2FPT0WU
CHP-134	M{T0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnTeZd5UUN3ME2xMlM4QDR2IN88US=>	M{T6cXNCVkeHUh?=
SW872	M2HtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTFwM{i1OVUh\|ryP	M17XRnNCVkeHUh?=
LB831-BLC	MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmr0TWM2OD1zLkO5NFY4KM7:TR?=	Mm\3V2FPT0WU
TE-12	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV35XI86UUN3ME2xMlQxPjBzIN88US=>	NUXv[VR3W0GQR1XS
LCLC-97TM1	M2ewe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrl[FJKSzVyPUGuOFExPDZizszN	M2TLZXNCVkeHUh?=
HCT-116	M2HRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17sS2lEPTB;MT60Nlg2PCEQvF2=	NYDsfnBQW0GQR1XS
ALL-PO	NEizfoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1P4V2lEPTB;MT60N\|c4PCEQvF2=	MlfVV2FPT0WU
EW-16	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljaTWM2OD1zLkSzPFQzKM7:TR?=	M4G0R3NCVkeHUh?=
NCI-H661	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfv[4pzUUN3ME2xMlQ1Pzd3IN88US=>	NEfmfW9USU6JRWK=
TE-8	M{jmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXZXFNWUUN3ME2xMlQ2PTZizszN	NWTT[YFNW0GQR1XS
TCCSUP	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTFwNE[5OkDPxE1?	MmnwV2FPT0WU
SW1990	NF3ySnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M122OGlEPTB;MT60O\|U{OyEQvF2=	NWjaN5A6W0GQR1XS
UM-UC-3	NIfjT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTFwNEe2O\|Uh\|ryP	M3P2OnNCVkeHUh?=
HuP-T4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTFwNEi2NFch\|ryP	M3Gw[nNCVkeHUh?=
NCI-H1299	NHLjSHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHKyOXRKSzVyPUGuOVAxQDZizszN	MmnDV2FPT0WU
RO82-W-1	M4nKU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LzUmlEPTB;MT61NlA5OSEQvF2=	NGqzdoVUSU6JRWK=
Becker	NYexXo9[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIj0N25KSzVyPUGuOVIyQDdizszN	MWjTRW5ITVJ?
SNU-387	NWjkcW9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvObnd5UUN3ME2xMlUzOjRzIN88US=>	NXq2V\|VKW0GQR1XS
CAL-85-1	NYPGZW9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;uc2lEPTB;MT61NlU6QSEQvF2=	NYnMVmRkW0GQR1XS
647-V	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTFwNUO4PEDPxE1?	NGDNTW5USU6JRWK=
SBC-5	NYXNT2RFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnTcnF5UUN3ME2xMlU1PTl\|IN88US=>	MkHwV2FPT0WU
NCI-H23	NHLOb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTSTWM2OD1zLkW1O\|E1KM7:TR?=	M3HaTnNCVkeHUh?=
CGTH-W-1	MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvBTWM2OD1zLkW1PFE6KM7:TR?=	MljnV2FPT0WU
SK-N-FI	M4ToZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEX5XFlKSzVyPUGuOVU6ODhizszN	MVfTRW5ITVJ?
KM-H2	M2nHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYf3WW9QUUN3ME2xMlU3PDd2IN88US=>	MWnTRW5ITVJ?
KY821	NELoZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LRTGlEPTB;MT61OlYyPyEQvF2=	MW\TRW5ITVJ?
RH-1	MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDXTWM2OD1zLkW2O\|YzKM7:TR?=	NV3P[3RuW0GQR1XS
KYSE-270	NGDQZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXDN5BKSzVyPUGuOVc1OjNizszN	MWXTRW5ITVJ?
SF539	NYToNZJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDGTWM2OD1zLkW3PVY6KM7:TR?=	NEXpUmhUSU6JRWK=
JEG-3	NFnY[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\hOo5{UUN3ME2xMlU5ODl2IN88US=>	MkLsV2FPT0WU
SCC-25	MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEf0WZBKSzVyPUGuOVg1OzJizszN	M1qxcnNCVkeHUh?=
SW1573	M1vKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7n[HRKSzVyPUGuOlAyPThizszN	MUfTRW5ITVJ?
EW-1	NXXrO3ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTFwNkGzOVEh\|ryP	MUnTRW5ITVJ?
YKG-1	M4XhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17xUmlEPTB;MT62NVQ{QCEQvF2=	NGHYdIFUSU6JRWK=
EW-11	MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3VXVdKSzVyPUGuOlE4PDFizszN	M{[wcXNCVkeHUh?=
DJM-1	NGLTZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTFwNkG4NlUh\|ryP	M2W5SnNCVkeHUh?=
Calu-3	M4nubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\0cmlEPTB;MT62OVIyOyEQvF2=	M{jMb3NCVkeHUh?=
HT-3	NHjPepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTFwNkW2OkDPxE1?	Mn7WV2FPT0WU
NCI-H69	M4K4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;nSY1mUUN3ME2xMlY4OzR\|IN88US=>	MUPTRW5ITVJ?
NCI-H2126	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPOPHc1UUN3ME2xMlY4Pzl5IN88US=>	Moi2V2FPT0WU
RPMI-2650	NGKxTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jCcGlEPTB;MT62PFMyPyEQvF2=	MofKV2FPT0WU
TE-6	NFP1R2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTFwN{C4O\|Qh\|ryP	Mn3KV2FPT0WU
MDA-MB-231	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTFwN{G5PVMh\|ryP	MX;TRW5ITVJ?
A2780	NVvCZ3VlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTFwN{KyNFch\|ryP	M3fhNnNCVkeHUh?=
GOTO	NVX2XIxvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M163bGlEPTB;MT63N\|U3KM7:TR?=	NWDseoJIW0GQR1XS
KYSE-70	NUDT[lZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHS2Z\|RKSzVyPUGuO\|Q1PDJizszN	NYrtTYlUW0GQR1XS
GMS-10	M2H2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLvWnhKSzVyPUGuO\|Q3PjJizszN	NIjTVJBUSU6JRWK=
CaR-1	NFu5cXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTY[VRMUUN3ME2xMlc1QDF{IN88US=>	MYjTRW5ITVJ?
SW900	NHS0dHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHw[FZKSzVyPUGuO\|Q6QTNizszN	MmnwV2FPT0WU
BB49-HNC	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHFT4ZKSzVyPUGuO\|UyPjhizszN	MWTTRW5ITVJ?
SNB75	MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HXUmlEPTB;MT63OVQ6OiEQvF2=	MVfTRW5ITVJ?
SK-PN-DW	NGT5NlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTFwN{W2PFIh\|ryP	MVHTRW5ITVJ?
5637	NV64dlNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmX5TWM2OD1zLke3NlY5KM7:TR?=	NE\0NoJUSU6JRWK=
BT-474	M3;VW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTFwN{ixO\|Eh\|ryP	MoHPV2FPT0WU
KM12	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXHTWM2OD1zLke5O\|QyKM7:TR?=	M4HqUnNCVkeHUh?=
COLO-680N	Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULuT4I4UUN3ME2xMlgzOzhzIN88US=>	MYLTRW5ITVJ?
Saos-2	MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoGxTWM2OD1zLkiyOFQ2KM7:TR?=	NFHiZoFUSU6JRWK=
CAL-54	M1vpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHCW3AxUUN3ME2xMlg{OzF\|IN88US=>	NYfSeWpNW0GQR1XS
U-118-MG	NVrHeJJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmf3TWM2OD1zLki0OlIzKM7:TR?=	M{W5cXNCVkeHUh?=
TGBC24TKB	NH\QOVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17ZXWlEPTB;MT64OVUxOSEQvF2=	MWnTRW5ITVJ?
NCI-H2052	M{n0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2S1fmlEPTB;MT64OlQyKM7:TR?=	NVjCV4JuW0GQR1XS
BB30-HNC	NW[xbWNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHrUoxKSzVyPUGuPFY1PjJizszN	MWDTRW5ITVJ?
KNS-81-FD	Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTFwOEmxOlUh\|ryP	MUnTRW5ITVJ?
HN	NUDqUXV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4mzVGlEPTB;MT64PVU1PSEQvF2=	MUfTRW5ITVJ?
ACHN	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTFwOUC3PFYh\|ryP	NXzkU3N[W0GQR1XS
HSC-2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\wbmlEPTB;MT65NVA6PiEQvF2=	M{TLeXNCVkeHUh?=
HCC2998	NVHlcYxVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{i4VGlEPTB;MT65N\|MzPSEQvF2=	MorJV2FPT0WU
HEL	NY\pW3BpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkCzTWM2OD1zLkm0NVg1KM7:TR?=	NVXiSmtJW0GQR1XS
SW684	NEjNSHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfEbpRKSzVyPUGuPVc{PzFizszN	MVLTRW5ITVJ?
NCI-H1693	M{TibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfLUVNKSzVyPUGuPVgxQDZizszN	Ml74V2FPT0WU
8-MG-BA	NWi2W2ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnf0TWM2OD1zLkm4NlEh\|ryP	MUDTRW5ITVJ?
OVCAR-8	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDRTWM2OD1{LkCwNlk2KM7:TR?=	MYrTRW5ITVJ?
DSH1	MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvaTWM2OD1{LkCxO\|c1KM7:TR?=	NYHBNXFpW0GQR1XS
KYSE-520	NYD3c\|lVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnQfHFzUUN3ME2yMlAzODR7IN88US=>	NWn3OVZPW0GQR1XS
GB-1	NW\yOYo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPjSmRKSzVyPUKuNFI2PzdizszN	NHm5TXdUSU6JRWK=
RCC10RGB	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTJwMES4O\|Eh\|ryP	MmXhV2FPT0WU
SW954	NYLtU2R6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTJwMEWwN\|Yh\|ryP	MVzTRW5ITVJ?
IST-MES1	M3yyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTGXFFwUUN3ME2yMlA2PTZ6IN88US=>	MYXTRW5ITVJ?
AU565	NIC1eHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjYR2NFUUN3ME2yMlA2QTB3IN88US=>	NYP0ZldKW0GQR1XS
CW-2	M2fmWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVi1UFk2UUN3ME2yMlA3QDd3IN88US=>	Mm\pV2FPT0WU
TE-1	NX7OTVBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XYUGlEPTB;Mj6wPVM4PyEQvF2=	MWHTRW5ITVJ?
KP-4	M{nKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrITFBNUUN3ME2yMlExOzF{IN88US=>	Ml\XV2FPT0WU
SNU-C2B	M2nyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTJwMUC4NlMh\|ryP	MVvTRW5ITVJ?
NCI-H1395	MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3[4Z2lEPTB;Mj6xNFk5PiEQvF2=	M12xdnNCVkeHUh?=
CAS-1	Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTJwMUG1OFYh\|ryP	NHLQTndUSU6JRWK=
NCI-H1155	NGPzPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXK3O2lrUUN3ME2yMlIzPjlizszN	NWriZYE2W0GQR1XS
SK-MEL-1	Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTJwMkixPFEh\|ryP	NHO4UYpUSU6JRWK=
KINGS-1	NXLYOZMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDEOpVzUUN3ME2yMlMxODh6IN88US=>	NUnjN5JlW0GQR1XS
ESS-1	NVjmcplKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGm1VFlKSzVyPUKuN\|A2OSEQvF2=	MUPTRW5ITVJ?
PANC-10-05	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzqfnZ[UUN3ME2yMlM4ODJ2IN88US=>	M4LXfXNCVkeHUh?=
HT-1376	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHFe29KSzVyPUKuN\|g4ODhizszN	NWHUWJY6W0GQR1XS
LS-513	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLPTWM2OD1{LkO4PFc1KM7:TR?=	MWjTRW5ITVJ?
KNS-42	NIL2c2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH:0dlRKSzVyPUKuN\|kyODVizszN	NFuzSGhUSU6JRWK=
639-V	NFzwXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDsTWM2OD1{LkSyO\|U5KM7:TR?=	NF7qTXlUSU6JRWK=
SJRH30	NXjUUnoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDNO3V6UUN3ME2yMlQ2OTZzIN88US=>	MYrTRW5ITVJ?
SW1783	NEnNR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTJwNEewO\|gh\|ryP	NEPBXo9USU6JRWK=
NB6	M1vnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTJwNEiyPEDPxE1?	MomxV2FPT0WU
SK-MEL-30	NGLNTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLDTWM2OD1{LkS4PFMh\|ryP	NF3YSZRUSU6JRWK=
HCE-4	NEfyd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTJwNEm0NFIh\|ryP	M3HuNnNCVkeHUh?=
NB10	M3zrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPPeohKSzVyPUKuOFk1OjlizszN	NYThTJF{W0GQR1XS
H-EMC-SS	M1\NUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTJwNUS2OUDPxE1?	NXXrd5E1W0GQR1XS
SK-HEP-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTJwNUWyN\|Yh\|ryP	M3LnPHNCVkeHUh?=
HCC1395	M37WW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfrUnB5UUN3ME2yMlU2PjV3IN88US=>	MXLTRW5ITVJ?
HuCCT1	M3HUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTJwNU[zPUDPxE1?	NIXWUGtUSU6JRWK=
SiHa	M2fIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofjTWM2OD1{LkW4O\|E6KM7:TR?=	MWDTRW5ITVJ?
EFO-21	NED6NY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTJwNUi3OlQh\|ryP	NV;k[m9tW0GQR1XS
NCI-H1666	NILITlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDVTWM2OD1{LkW5NFc3KM7:TR?=	NYDNO4NxW0GQR1XS
UMC-11	MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTJwNUm4Olgh\|ryP	M{jtbHNCVkeHUh?=
COLO-679	NELjfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDPW4RKSzVyPUKuOlEzOzNizszN	M3HCVnNCVkeHUh?=
A388	NYi4SZhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXBNXJiUUN3ME2yMlY2OjV\|IN88US=>	MYLTRW5ITVJ?
LB2518-MEL	M4Ho[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\JU25MUUN3ME2yMlY2PDB6IN88US=>	M1v2VnNCVkeHUh?=
EW-13	NVLZb5hJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTJwNki3Olgh\|ryP	MkjtV2FPT0WU
MLMA	MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofpTWM2OD1{Lk[4PFU3KM7:TR?=	NEDS[5NUSU6JRWK=
HOP-92	NFrK[\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILqcHVKSzVyPUKuO\|AyOSEQvF2=	M4K1VHNCVkeHUh?=
NOMO-1	NYXNcW41T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3H1NGlEPTB;Mj63NVQ1OiEQvF2=	NXTuWVVDW0GQR1XS
NCI-H810	MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLYTWM2OD1{LkeyNVk5KM7:TR?=	Mn7CV2FPT0WU
769-P	NFSwbWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;wSWlEPTB;Mj63NlI5KM7:TR?=	NXnwSYdNW0GQR1XS
SAS	MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTJwN{[1JO69VQ>?	Mo\5V2FPT0WU
M059J	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;MTWM2OD1{Lke4N\|E5KM7:TR?=	NXfvVphpW0GQR1XS
RD	MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvQNZZKSzVyPUKuO\|k1PzFizszN	NVfYPId{W0GQR1XS
GT3TKB	M2nlZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DCeWlEPTB;Mj64N\|Q{OyEQvF2=	M1W1enNCVkeHUh?=
MZ7-mel	M4nwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{n3UGlEPTB;Mj64OlUxOiEQvF2=	NHXjcWdUSU6JRWK=
KYSE-510	M2nWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLndXZjUUN3ME2yMlg6PTB2IN88US=>	MWPTRW5ITVJ?
NCI-N87	NWrIRo9CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTJwOUG4NFch\|ryP	Ml3BV2FPT0WU
MKN1	MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HnUmlEPTB;Mz6wNFE3OyEQvF2=	MWXTRW5ITVJ?
NCI-H2170	MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXWenp1UUN3ME2zMlAxPDVzIN88US=>	NI[zSXlUSU6JRWK=
OVCAR-3	M{LLNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XOSmlEPTB;Mz6wNlEyPSEQvF2=	MmHSV2FPT0WU
KLE	MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;NTWM2OD1\|LkC2PFEzKM7:TR?=	MUjTRW5ITVJ?
LB771-HNC	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrITWM2OD1\|LkC5N\|Q{KM7:TR?=	MXXTRW5ITVJ?
MC116	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjuR21KSzVyPUOuNVEyOTJizszN	M2m4eXNCVkeHUh?=
SCC-9	NIHORllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXtTWM2OD1\|LkGxN\|Y3KM7:TR?=	M4LKUnNCVkeHUh?=
U031	NF[zZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rF[GlEPTB;Mz6xNlQzOyEQvF2=	M4jHdXNCVkeHUh?=
LCLC-103H	MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlz5TWM2OD1\|LkKzPFk1KM7:TR?=	MkXVV2FPT0WU
U-266	MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3:1Z2lEPTB;Mz6yO\|Y{OyEQvF2=	M1K4NXNCVkeHUh?=
JVM-2	M3n0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvkb3hKSzVyPUOuN\|IyPjRizszN	NXTPVW91W0GQR1XS
UACC-257	M2XxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHZVWlqUUN3ME2zMlQ3PDNzIN88US=>	MkLjV2FPT0WU
LB996-RCC	MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1frNGlEPTB;Mz60OlUxOiEQvF2=	MkP5V2FPT0WU
BT-549	NHf4WYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrXbVFKSzVyPUOuOVAzODlizszN	NHq1c3ZUSU6JRWK=
NCI-H526	NVn6bFh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTHTWM2OD1\|LkW0NVU5KM7:TR?=	NVjTTolTW0GQR1XS
RH-18	NHPreWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTNwNkG3PVgh\|ryP	NYHub3BjW0GQR1XS
SW626	MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XmXGlEPTB;Mz63NVEzQCEQvF2=	NHzkVIhUSU6JRWK=
SK-N-AS	Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XKW2lEPTB;Mz63N\|I1PyEQvF2=	NVr2VIU4W0GQR1XS
IGR-1	NY\yfJdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLQboJKSzVyPUOuO\|QzPDhizszN	MoizV2FPT0WU
NCI-H2291	M2DveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTIT2RKSzVyPUOuO\|U{OzZizszN	NInheVJUSU6JRWK=
NCI-H441	MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTNwOEK0N\|Mh\|ryP	MnPtV2FPT0WU
D-247MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rQbGlEPTB;Mz64OlA{OSEQvF2=	MYHTRW5ITVJ?
COLO-320-HSR	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\QT2k3UUN3ME2zMlkyOjdzIN88US=>	M3HV[XNCVkeHUh?=
A253	Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PQfmlEPTB;Mz65NVQ{PiEQvF2=	M1jWUnNCVkeHUh?=
HT55	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3T1[2lEPTB;Mz65NVc4OyEQvF2=	MVnTRW5ITVJ?
MZ1-PC	M4Xp[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjRTWM2OD1\|Lkm1PFY1KM7:TR?=	NGrr[oxUSU6JRWK=
RERF-LC-MS	NGeyPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrMSoVKSzVyPUOuPVY2OjVizszN	MYnTRW5ITVJ?
SF268	M3Pa[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTPbnNjUUN3ME20MlEzQDhzIN88US=>	NXW2UWw{W0GQR1XS
RMG-I	NYi0Ro9bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTRwMkG0OVQh\|ryP	NHXSe2hUSU6JRWK=
CFPAC-1	NGLQdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PqVmlEPTB;ND6yNVY5PSEQvF2=	M4DY[HNCVkeHUh?=
S-117	NVHVflFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvTdZhKSzVyPUSuNlIxOjRizszN	MUjTRW5ITVJ?
NCI-H2122	MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zBWmlEPTB;ND6zNFk{OSEQvF2=	MnnOV2FPT0WU
J82	M{ewRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnhTWM2OD12LkOzOFQyKM7:TR?=	M1j4O3NCVkeHUh?=
CAL-72	NF;yco1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTOTWM2OD12LkO1OFc4KM7:TR?=	Moe4V2FPT0WU
GP5d	NF24NHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrOVVZKSzVyPUSuOFEzQThizszN	MlHDV2FPT0WU
UACC-62	M1LGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmS1TWM2OD12LkS2OVQ2KM7:TR?=	NUjLPYNHW0GQR1XS
MS-1	M2jpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HvZ2lEPTB;ND60PVEyPSEQvF2=	M{S3XHNCVkeHUh?=
RCM-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nJNGlEPTB;ND61NlkzKM7:TR?=	MUDTRW5ITVJ?
IST-SL1	NYjWRm1TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;zSYNGUUN3ME20MlY2OzV7IN88US=>	MYjTRW5ITVJ?
SW756	NVLwN4VNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTRwNkmxN\|Uh\|ryP	NUjRfINQW0GQR1XS
HCC38	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fXbmlEPTB;ND63NVE6PyEQvF2=	M1\lUXNCVkeHUh?=
YAPC	NW[1ZlNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDEeHI1UUN3ME20MlcyOzF\|IN88US=>	M1XjR3NCVkeHUh?=
DK-MG	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvEWoNKSzVyPUSuO\|gyOTJizszN	MVPTRW5ITVJ?
HCC1937	NUDud2Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\tfI5KSzVyPUSuPFUyOjVizszN	MY\TRW5ITVJ?
OAW-28	NGLhSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTafnZWUUN3ME20MlkzPDN3IN88US=>	Mn74V2FPT0WU
MEG-01	MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTVwMEizNlgh\|ryP	Ml3VV2FPT0WU
GI-1	NUTF[nlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYH2[FhZUUN3ME21MlI{PDh4IN88US=>	MUHTRW5ITVJ?
FADU	M2nsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXie\|lKSzVyPUWuNlc5OzdizszN	NYPH[m1VW0GQR1XS
CAPAN-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\QTWM2OD13LkO5OFMzKM7:TR?=	NWroZ4dnW0GQR1XS
TGBC11TKB	MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYC2fphqUUN3ME21MlQ2Pzh4IN88US=>	Mm\HV2FPT0WU
DBTRG-05MG	NUPqTIU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTVwNUC1NkDPxE1?	NFzlfVdUSU6JRWK=
ONS-76	NXTVfHBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nIe2lEPTB;NT61OVgxOSEQvF2=	Mk\IV2FPT0WU
Ca-Ski	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TTUWlEPTB;NT62NlU3PiEQvF2=	NFfMUpJUSU6JRWK=
COLO-741	NUj0[ZVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlT1TWM2OD13LkexPVk2KM7:TR?=	MU\TRW5ITVJ?
HT-29	Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkT1TWM2OD13LkiwOFc2KM7:TR?=	NFHKfIVUSU6JRWK=
HCC1187	NWPVZnVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTVwOEGwNFgh\|ryP	M33BeHNCVkeHUh?=
Capan-2	NVLKRpR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjKe2M6UUN3ME21Mlk2QTl2IN88US=>	MlzxV2FPT0WU
NCI-H630	NVyyTmsxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF[xeIpKSzVyPU[uNVE1PDFizszN	MYHTRW5ITVJ?
COLO-678	M2TyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXuTWM2OD14LkG1NFkzKM7:TR?=	MkHuV2FPT0WU
D-502MG	NWf3PXNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\VSmlEPTB;Nj6xO\|M{PiEQvF2=	MlzsV2FPT0WU
NB17	NHO3[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELM[WJKSzVyPU[uNlQ6PDNizszN	NFHhemZUSU6JRWK=
SK-MEL-24	NYriRZJOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTZwMk[0PUDPxE1?	MWDTRW5ITVJ?
NCI-SNU-5	M1jCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXZTWM2OD14LkK3NVE5KM7:TR?=	MYnTRW5ITVJ?
D-392MG	MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrHSmxTUUN3ME22MlM{Ozl7IN88US=>	M4PN[3NCVkeHUh?=
A498	M2f0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTZwNECzNFIh\|ryP	Mn3kV2FPT0WU
OCI-AML2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nmZmlEPTB;Nj60OVQ1PSEQvF2=	MVrTRW5ITVJ?
HCC2157	NHXTdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPNU4hKSzVyPU[uOFU3OTZizszN	M4XyRnNCVkeHUh?=
C3A	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnK3TWM2OD14LkWyNFA1KM7:TR?=	M3W5dHNCVkeHUh?=
NCI-H1650	M{XIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXNTWM2OD14LkewOVIzKM7:TR?=	MmDoV2FPT0WU
DU-145	NHPaVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rVUGlEPTB;Nj63O\|A{KM7:TR?=	NYniSGtLW0GQR1XS
COLO-829	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnoTWM2OD14Lke3PFc{KM7:TR?=	MkDvV2FPT0WU
LS-1034	Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTdwMES0NVIh\|ryP	NH\HN4pUSU6JRWK=
HCC1954	M4DXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jvZ2lEPTB;Nz60PFE{PCEQvF2=	NYrKfZJrW0GQR1XS
KURAMOCHI	Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTdwNEi1N\|Mh\|ryP	MWnTRW5ITVJ?
Mo-T	NFzkeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDvZWNKSzVyPUeuOVE1QThizszN	NYfCU215W0GQR1XS
OE19	NXTwcWlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnMTWM2OD15Lk[1OVA{KM7:TR?=	MVrTRW5ITVJ?
COR-L105	MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXKT2RFUUN3ME23MlcyPDJzIN88US=>	NFfwNVVUSU6JRWK=
NCI-H2342	MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknMTWM2OD15LkexOVIyKM7:TR?=	M2D4bnNCVkeHUh?=
U-87-MG	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk[0TWM2OD16LkCzN\|M1KM7:TR?=	NXTJOYFYW0GQR1XS
MKN28	NFnqeW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzTTWM2OD16LkGxOVE2KM7:TR?=	NVnMRnRxW0GQR1XS
HT-1197	NXTmd\|Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3pTWM2OD16LkK1PVA4KM7:TR?=	Mm\SV2FPT0WU
ChaGo-K-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWruZ4VpUUN3ME24MlM1OjR3IN88US=>	NXrOWZJ5W0GQR1XS
NCI-H226	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HicWlEPTB;OD60OFM{OSEQvF2=	M4qzRnNCVkeHUh?=
NCI-H2029	M37Cbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTlwME[3OVkh\|ryP	M{HUTnNCVkeHUh?=
TE-11	Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIi4cGtKSzVyPUmuOFU2QDhizszN	MUXTRW5ITVJ?
ZR-75-30	M{[4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGH5V\|dKSzVyPUmuPVI3OzRizszN	M1zyZ3NCVkeHUh?=
SW837	MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVztXVFGUUN3ME2xNE4zOjl\|IN88US=>	M{nsTnNCVkeHUh?=
NCI-H1651	NUjNTW1XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHPR3BKSzVyPUGwMlI{OjZizszN	NYXjN4pDW0GQR1XS
NCI-H727	NYrOU3Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jVcGlEPTB;MUCuOFQ6PSEQvF2=	MnLyV2FPT0WU
NCI-H358	M3PNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHWVoFKSzVyPUGwMlg{PjVizszN	MWPTRW5ITVJ?
NCI-H2087	NUfJbmlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTFzLkC0N\|Qh\|ryP	M3vsZXNCVkeHUh?=
FTC-133	NHH6TWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjFTWM2OD1zMT60NFUyKM7:TR?=	M4jCb3NCVkeHUh?=
LAN-6	MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETwflBKSzVyPUGyMlEzPCEQvF2=	NIexS5FUSU6JRWK=
NCI-H1838	M1raXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWT3Ro5RUUN3ME2xNk42OTVzIN88US=>	MnfQV2FPT0WU
Calu-6	NU\w[3JnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\rSZZKSzVyPUG0MlExOjFizszN	Mly0V2FPT0WU
HCC70	M2jNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jLc2lEPTB;MUSuOFUyKM7:TR?=	NFzwdVlUSU6JRWK=
KARPAS-299	M3Wy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{i0RmlEPTB;MUWuNlE2QSEQvF2=	NFLYPJBUSU6JRWK=
CAL-27	M1TGS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmG4TWM2OD1zNT6zPFQ{KM7:TR?=	NFLsPJNUSU6JRWK=
NCI-H82	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXlTWM2OD1zNT61N\|Ih\|ryP	MoDoV2FPT0WU
no-10	NET0[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFuxXHdKSzVyPUG1Mlk{QCEQvF2=	NFnvfHZUSU6JRWK=
U251	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGO5XIRKSzVyPUG2MlM3PzVizszN	NFLQOoJUSU6JRWK=
TE-9	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXzTWM2OD1zNz61NVY3KM7:TR?=	MXTTRW5ITVJ?
TE-10	M13QfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3DdI9KSzVyPUG5MlA3ODdizszN	M3jSRnNCVkeHUh?=
COLO-824	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3ITWM2OD1{MD65Nlc3KM7:TR?=	MnTCV2FPT0WU
HuP-T3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWqyUW56UUN3ME2yNU4xPzR6IN88US=>	NGj3S5pUSU6JRWK=
KALS-1	M3jodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWL4bHdjUUN3ME2yNU4yPzVizszN	MUHTRW5ITVJ?
L-428	M13ROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzm[YxKSzVyPUKxMlQxOTZizszN	MWPTRW5ITVJ?
JAR	NIPGSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXq[o9CUUN3ME2yNU42ODJizszN	NGnEUI1USU6JRWK=
DoTc2-4510	NXjY[o9sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTvclhLUUN3ME2yN{45PDd3IN88US=>	NITESFVUSU6JRWK=
ABC-1	NWGzfIFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkH4TWM2OD1{Nj63PVU4KM7:TR?=	NFrVcmFUSU6JRWK=
MHH-NB-11	NGL3PWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfN[VFKSzVyPUOzMlM1PjRizszN	NYrtUJZXW0GQR1XS
SW1463	MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;UVm1KSzVyPUOzMlk5OyEQvF2=	MVHTRW5ITVJ?
SW1417	NIW4UIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3rTWM2OD1\|Nz6wPVUzKM7:TR?=	NGnYOm1USU6JRWK=
NB12	NX7VV5NxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrUblJKSzVyPUO5MlQ3PTVizszN	NH\MZo9USU6JRWK=
NY	M3v2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTRzLkOyNFEh\|ryP	M1zUe3NCVkeHUh?=
H1048	NXnkRm5RSXCxcITvd4l{KEG\|c3H5	NIjYWYY2ODBibl2=	MXS3NkBp		NX\wS3dqdmijbnPld{BCSlRvMk[z5qCUcW6mdXPl[EBieG:ydH;zbZM>	NGDwNoszPTd\|N{W0Ni=>
H86	M{XQOWFxd3C2b4Ppd{BCe3OjeR?=	NF3TTHc2ODBibl2=	MWK3NkBp		NHe1XGpvcGGwY3XzJGFDXC1{NkRihLNqdmS3Y3XkJIFxd3C2b4Ppdy=>	MYGyOVc{PzV2Mh?=
H196	MlT2RZBweHSxc3nzJGF{e2G7	NYX6dlh1PTByIH7N	M3PjflczKGh?		NXnKb4ZvdmijbnPld{BCSlRvMk[z5qCUcW6mdXPl[EBieG:ydH;zbZM>	NFLjTZkzPTd\|N{W0Ni=>
H446	MmPSRZBweHSxc3nzJGF{e2G7	M4fLVlUxOCCwTR?=	MWS3NkBp		NEfIO2tvcGGwY3XzJGFDXC1{NkRihLNqdmS3Y3XkJIFxd3C2b4Ppdy=>	M{fNSlI2PzN5NUSy
TFK-1	M4nCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFvOT\|Y4OiCq	NFj6b5lFVVOR	MVfJR\|UxRTR5IH7N	NV:5OFhiOjVzNUKyOFQ>
EGI-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVi3NkBp	MXTEUXNQ	NG\PNJBKSzVyPUWzJI5O	MXqyOVE2OjJ2NB?=
OCI/AML3	M3Tlemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nBTFAvOiEQvF2=	Mlv5OFghcA>?		M4DPd4VvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iaX7keYNm\CCkeTDz[Yx2dWW2aX7pZi=>	MoHCNlQ4Ozl\|OUO=
U937	M{\Nd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnxd5FxOC5{IN88US=>	M4jZbFQ5KGh?		NETrUXVmdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHnu[JVk\WRiYomgd4VtfW2ndHnubYI>	M1njWFI1PzN7M{mz
MOLM13	NXnRemNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHy1N2gxNjJizszN	MX60PEBp		NWTidVYz\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDpcoR2[2WmIHL5JJNmdHWvZYTpcolj	M{ezfFI1PzN7M{mz
MCF7	Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7rVZgzOCCwTR?=	NFrLSo04OiCq	M1LGSGZDWw>?	NW\3SVRQemWmdXPld{B1cGViUFXMVFEudWWmaXH0[YQhcW6lcnXhd4UhcW5iY3XscEB3cWGkaXzpeJk>	Mlj0NlQ3QDhyNE[=
TamR	M{fyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIG2VGZKSzVyPUG45qCKdk1?	MWmyOFQ2PzB4OR?=
MCF7-X	Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3TN2hlUUN3ME2yOEBvVQ>?	M4raflI1PDV5ME[5
T47D-tamR	M4XDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfJTWM2OD1zOTDuUS=>	NUHGfY1ROjR2NUewOlk>
293T	MUnGeY5kfGmxbjDBd5NigQ>?	MnS2NlAhdk1?	MVqzJIg>		M2TJRoRqe3K3cITzJGFsfC2vZXTpZZRm\CCWSV[tTWEhe3SjYnnsbZR6NCC2cnHud4xw[2G2aX;uMEBidmRiYXP0bZZqfHl?	NIjJNpAzPDN4M{S0PS=>
SW620	M3PkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkC2NE4xODFvMUFOwG0>	NVrVOFBJOjRiaB?=		MV\pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGG\|IITo[UBkd26lZX70doF1cW:wIILpd4V{	NWTOWYxDOjR\|NkO0OFk>
Huh7	M3KwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjx[GU2NTFyMDDuUS=>	NHHmeHcxNTJ2IHi=	NWTXOINHTE2VTx?=	NHLpNmxqdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	NUHsboFLOjR{OUezNFA>
Hep3B	NYDhUVVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2foWlUuOTByIH7N	MnLmNE0zPCCq	NF:3WJlFVVOR	M{Gyd4lv[3KnYYPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MXGyOFI6PzNyMB?=
Huh7	MmHISpVv[3Srb36gRZN{[Xl?	NFvv[ZUyODBibl2=	MXqxNkBp	M{fnSGROW09?	MmfVbY5lfWOnczDheZRweGijZ4pCpC=>	MnnMNlQzQTd\|MEC=
U87-MG	M3z0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3X2dlczKGh?		MUTHTVUx6oDLPfMAjVc6KG6PwrC=	M1PjNlI1OjR7NkSw
L3.6pl	NXvscI42T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\JRpkzOSEQvF2=	NVTic5M2PzJiaB?=		NV;XVZJScW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwdWKrbnXkJJdqfGhiQl3TMVc4PzZyNx?=	M1PFUVI1OjN\|M{m5
TE671	NFLZd\|RCeG:ydH;zbZMhSXO\|YYm=	NXXhdHFYOSEQvF2=	MmPkOFghcA>?		NUS1PJpScW6lcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhSUKWLUezOy=>	Mn;ZNlQyOzN{MUi=
RD	MUfBdI9xfG:\|aYOgRZN{[Xl?	MoX3NUDPxE1?	NVyz[pR6PDhiaB?=		NV\vWpM5cW6lcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhSUKWLUezOy=>	MXuyOFE{OzJzOB?=
RMS13	MlfKRZBweHSxc3nzJGF{e2G7	MkG5NUDPxE1?	NWLuV2N1PDhiaB?=		NInKclNqdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUBCSlRvN{O3	MUGyOFE{OzJzOB?=
RH30	NYnU[mNySXCxcITvd4l{KEG\|c3H5	MUWxJO69VQ>?	MlfCOFghcA>?		M3vQ[4lv[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JGFDXC15M{e=	NELSXYkzPDF\|M{KxPC=>
Hep-2	NUjhdZVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfSNE4xOS1zIN88US=>	NH3hb5UyOi17NjDo		NWTIcYZncW6lcnXhd4V{KGOnbHyg[IVifGhiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	NXHydoZiOjRzMEO3OFk>
SCC-9	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4H6[\|AvODFvMTFOwG0>	MUCxNk06PiCq		NWLVTnczcW6lcnXhd4V{KGOnbHyg[IVifGhiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	MY[yOFExOzd2OR?=
Hep-2	MlLUSpVv[3Srb36gRZN{[Xl?	MYCwMlEwOC53IN88US=>	NV\yTYVJOjRiaB?=		MYnicI9kc3NibWTPVmMyKGGwZDDtWG9TSzJiYXP0bZZifGmxbh?=	NHvzU2IzPDFyM{e0PS=>
SCC-9	MUDGeY5kfGmxbjDBd5NigQ>?	NUjucoJIOC5zL{CuOUDPxE1?	MYqyOEBp		MoXUZoxw[2u\|IH3UU3JEOSCjbnSgcXRQWkN{IHHjeIl3[XSrb36=	M1q3RlI1OTB\|N{S5
PANC-1	MVTBdI9xfG:\|aYOgRZN{[Xl?	MVm1NFAhdk1?	NInCT201QCCq		NUfW[WFIe2Wwc3n0bZpmeyCyYX7jdoVifGmlIHPhcoNmeiClZXzsd{B1dyC{YXTpc5Rp\XKjcIm=	MnjaNlM5QDZ{OUS=
RMG2	MX7BdI9xfG:\|aYOgRZN{[Xl?	NGDBWHYyNTFyMECgcm0>	MnPCO\|IhcA>?	MlK4SmJU	NXHWTXVYcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk>	M3WxVFI{PjF3NkOx
HAC2	M3ixVmFxd3C2b4Ppd{BCe3OjeR?=	MorQNU0yODByIH7N	NF7OTWI4OiCq	NVXSZnp{TkKV	MojsbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm=	M2fnZlI{PjF3NkOx
HT-29	NIexUHRCeG:ydH;zbZMhSXO\|YYm=	NGf4PJMyKM7:TR?=	NFPheI44OiCq		MV7heJRmdnWjdHXzJFUuTlVvaX7keYNm\CClZXzsJIRm[XSq	M3jzS\|IyQTR7MUKx
DLD1	NGHtVINCeG:ydH;zbZMhSXO\|YYm=	MUSxJO69VQ>?	M4LPcFczKGh?		NG\H[lRifHSnboXheIV{KDVvRmWtbY5lfWOnZDDj[YxtKGSnYYTo	NYPLRZZDOjF7NEmxNlE>
HT-29	NU\JdlhVTnWwY4Tpc44hSXO\|YYm=	NHWxZ4syKM7:TR?=	NIflfmo4OiCq		MkLRbY5lfWOnczDheZRweGijZ4mgeI8h[2:wZnXyJIN6fG:ycn;0[YN1cW:w	MUiyNVk1QTF{MR?=
DLD1	M2rmNWZ2dmO2aX;uJGF{e2G7	NWjmc41DOSEQvF2=	MUi3NkBp		M1HJW4lv\HWlZYOgZZV1d3CqYXf5JJRwKGOxbn\ldkBkgXSxcILveIVkfGmxbh?=	NX7MfGxiOjF7NEmxNlE>
Rh41	NF;COnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrXRnRKSzVyPUOwMlchdk1?	MkXzNlE{Ozd4N{m=
Rh18	M1LEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnO2TWM2OD12MT60JI5O	M36wdFIyOzN5Nke5
Rh30	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\ZTWM2OD1zNDDuUS=>	NET1RoEzOTN\|N{[3PS=>
BT-12	NX6ySlhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTJ2Lkegcm0>	MnexNlE{Ozd4N{m=
CHLA-266	NVTyWmI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTFwMTDuUS=>	M{PnOlIyOzN5Nke5
TC-71	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTR4LkWgcm0>	NF;x[2szOTN\|N{[3PS=>
CHLA-9	MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7CWFNKSzVyPUG1MlMhdk1?	M2PLfFIyOzN5Nke5
CHLA-10	NHLsWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnDNW5XUUN3ME2zMlkhdk1?	NH3CdlUzOTN\|N{[3PS=>
CHLA-258	Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fSWGlEPTB;MUCuOEBvVQ>?	NV3NUm1iOjF\|M{e2O\|k>
GBM2	M3jLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTRyLkegcm0>	NUDoWoNFOjF\|M{e2O\|k>
NB-1643	M3;aZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3aTWM2OD1\|Mz64JI5O	NF70eGczOTN\|N{[3PS=>
NB-EBc1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjVeJBKSzVyPUK3MlEhdk1?	NWLVdplwOjF\|M{e2O\|k>
CHLA-90	NEDhcmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXOTWM2OD1\|ND61JI5O	MYCyNVM{PzZ5OR?=
CHLA-136	NYezcZlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn74TWM2OD1zNkKuOkBvVQ>?	MUeyNVM{PzZ5OR?=
NALM-6	NYLBZYJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmi1TWM2OD1\|Mj65JI5O	NYWyVIFUOjF\|M{e2O\|k>
COG-LL-317	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILYfZJKSzVyPUGuN{BvVQ>?	MXWyNVM{PzZ5OR?=
RS4;11	MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHUfXd[UUN3ME2zOUBvVQ>?	M3ntelIyOzN5Nke5
MOLT-4	NY[2Unh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfyXWd4UUN3ME24MlYhdk1?	NH60ZY0zOTN\|N{[3PS=>
CCRF-CEM	MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTRwMTDuUS=>	M4f4NlIyOzN5Nke5
Kasumi-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTFwNDDuUS=>	MnfQNlE{Ozd4N{m=
Karpas-299	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVX6[mpHUUN3ME2yNU44KG6P	M3nsVFIyOzN5Nke5
Ramos-RA1	MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRThwMjDuUS=>	NWPuVnR[OjF\|M{e2O\|k>
H838	NXnpU5RQTnWwY4Tpc44hSXO\|YYm=	Mo\FNUDPxE1?	NWWwdJhiPDhiaB?=		MV;pcoR2[2W\|IHPlcIwh[XW2b4DoZYd6	NGCyfokzODN4NEGxNy=>
H838	NXjkVYd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\TfFIxOC1\|IN88US=>	NGjZNHg4OiCq		NYr2SXBIcW6mdXPld{Boem:5dHigbY5pcWKrdHnvckBidmRiYYX0c5Bp[We7	M1\1VlIxODJ6OEW0
A549	NYrwdZltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLJRlgzOC1\|IN88US=>	M{fnflczKGh?		Mm\abY5lfWOnczDndo94fGhiaX7obYJqfGmxbjDhcoQh[XW2b4DoZYd6	NUX6c5lnOjByMki4OVQ>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-mTOR / p-AKT / p-4EBP1 / p-P70S6K / p-PRAS40; PubMed: 24457069 Breast Cancer Res Western blots of 70% confluent TamR (A) and MCF7-X (B) cells treated for 15 minutes to 24 hours with AZD8055 (0 to 100 nM). Blots were probed with phospho- and total antibodies for mTORC1 and two signalling pathways. In both cell lines mTORC1 and mTORC2 s䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙 p-EGFR / EGFR; PubMed: 25654224 Int J Mol Sci PANC-1 cells were treated with AZD8055 for the indicated hours and EGFR (T/P), AKT (T/P) and ribosomal protein S6 (S6) (T/P) proteins were examined by western-blot; p-FOXO1 / FOXO1 / p-FOXO3a / FOXO3a ; PubMed: 25654224 Int J Mol Sci PANC-1 cells were transfected with FoxO1/FoxO3a siRNAs and treated with AZD8055 for 1 h, then AKT (T/P), FoxO1 (T/P), FoxO3a (T/P) and EGFR (T/P) proteins were examined by western-blot.	24457069 25654224
Immunofluorescence	p-4EBP1 / EIF4E / mTOR; PubMed: 24600487 Int J Clin Exp Med (C) Hoechst 33258 staining of Hep-2 cells after treatment with AZD8055 for 24 hours were shown. The cells were fixed and immunereacted with anti-mTOR antibody followed by incubation with Alexa 488-labeled secondary antibody (C-F). Images were taken by a c䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋à㺣痖�෋𢡄�෋䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemｾ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄堚،齃礤v�堞ﻮ᎒猢Wｾ᎒䨼Ą鹿齃殺獸W戀醙玛W戀ⶰ໯齃礤v 玚W玢Wⶰ໯﫰礌vtЉᔈැ鲬౴᥊疜犈፲Eo狜፲艘ᎂ艘ᎂ⩈̎䥠̌씢痗狠፲붖᎒i變ﱘ﫰﬐먙堘붖᎒狠፲i變ﱘ﫰먰堘ﱘ붖᎒�堞봆᎒릎堘붖᎒i꣩쯟巰痗ꣵ쯟巰痗Љ镴౴嶴痗Љ镨౴ᔈැ竗ᔈැ屷痗W竗尊痗 LC3B / p62 ; PubMed: 30337536 Cell Death Dis Immunofluorescence staining of U87 and U251 GICs, which treated by DMSO, AZD8055 (0.3 μM) and rapamycin (3 μM). The nuclei were stained with DAPI and the antibody against LC3B and p62. Images were captured by laser confocal microscope ( × 400), scale bar 䲧疝Ỵ疞	24600487 30337536
Growth inhibition assay	Cell viability ; PubMed: 29263324 Nat Commun Growth for the indicated cell lines was assessed after 72 h of treatment with AZD8055 (0–250 nM). Results are expressed as a percentage of cell number relative to the DMSO-treated control cells a.	29263324

In vivo

AZD8055 inhibits the pS6 and pAkt in U87MG and A549 xenografts at 2.5/10 mg/kg, which leads to tumor growth inhibition. AZD8055 shows significant antitumor activity in many xenografts, including U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA at a dose of 10/20 mg/kg. ^[1] AZD8055 induces ~40% reduction in tumour volume, accompanied by ablation of phosphorylation of Akt, S6K and SGK protein kinases. Administration of AZD8055 (5mg/kg, Bid) and SAHA (100 mg/kg/d) results in complete tumor growth inhibition in PTEN+/−LKB1+/hypo xenografts without side effects on mice by inhibition of mTORC1 and mTORC2 signaling. ^[4]

Protocol

Kinase Assay:^[1]	+ Expand Cell-based determinations of mTOR inhibition: A high-throughput screening cell-based assay is developed using MDA-MB-468 cells to detect mTORC1 and mTORC2 activity. Cells are exposed for 2 hours to increasing concentrations of AZD8055. At the end of the incubation period, cells are fixed, washed, and probed with antibodies against S473 pAkt or against S235/236 phosphorylated S6 (pS6). Levels of phosphorylation are assessed using an Acumen laser scanning cytometer.
Cell Research:^[1]	+ Expand Cell lines: U87MG, A549 and H838 cells Concentrations: 1 nM - 1 μM Incubation Time: 72 to 96 hours Method: Cells are exposed to AZD8055 for 72 to 96 hours and stained for cell nuclei (0.03 mg/mL Hoechst 33342) and acidic vesicles (1 μg/mL acridine orange). Images are captured at 450 and 536 nm on an ArrayScan II platform, and the percentage of acidic vesicles and the number of cells are quantified. For LC3 assessment, cells are exposed to e64d/pepstatin (10 μg/mL) for 30 to 90 min before incubation with AZD8055. Cells are lysed on ice and analyzed by immunoblotting. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA U87-MG and A549 are established in pathogen-free, female nude mice (nu/nu:Alpk). Formulation: Dissolved in captisol (CyDex, pH 3.0) and diluted to a final captisol concentration of 30% (w/v) Dosages: 2.5-20 mg/kg Administration: Oral gavage once or twice daily (Only for Reference)

References

[4] García-Martínez JM, et al. Br J Cancer, 2011, 104(7), 1116-1

+ Expand

Solubility (25°C)

In vitro	DMSO	50 mg/mL warmed (107.4 mM)
	Ethanol	3 mg/mL (6.44 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AZD8055 SDF

Molecular Weight	465.54
Formula	C₂₅H₃₁N₅O₄
CAS No.	1009298-09-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01316809	Completed	Glioblastoma Multiforme\|Anaplastic Astrocytoma\|Anaplastic Oligodendroglioma\|Malignant Glioma\|Brainstem Glioma	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	March 4 2011	Phase 1
NCT01316809	Completed	Glioblastoma Multiforme\|Anaplastic Astrocytoma\|Anaplastic Oligodendroglioma\|Malignant Glioma\|Brainstem Glioma	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	March 4 2011	Phase 1
NCT00999882	Completed	Cancer\|Advanced Hepatocellular Carcinoma	AstraZeneca	October 2009	Phase 1
NCT00999882	Completed	Cancer\|Advanced Hepatocellular Carcinoma	AstraZeneca	October 2009	Phase 1
NCT00973076	Completed	Cancer\|Solid Tumors\|Advanced Solid Malignancies	AstraZeneca	August 2009	Phase 1
NCT00973076	Completed	Cancer\|Solid Tumors\|Advanced Solid Malignancies	AstraZeneca	August 2009	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products4

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
Torin 1

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (INK 128, MLN0128,TAK-228)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

AZD8055

Cited by 47 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download AZD8055 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Choose Your Country or Region

By Signaling Pathways

By product type

AZD8055

Cited by 47 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download AZD8055 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)